Full Text View
Tabular View
No Study Results Posted
Related Studies
Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients
This study has been completed.
Study NCT00050999   Information provided by Eisai Inc.
First Received: December 31, 2002   Last Updated: February 29, 2008   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Lymphoma, T-Cell, Cutaneous
Mycosis Fungoides
Sezary Syndrome
Additional conditions recognized in this trial
Lymphoma
Lymphoma, T-Cell
Syndrome
More general conditions related to this trial
Disease
Immune System Diseases
Immunoproliferative Disorders
Lymphatic Diseases
Lymphoma, Non-Hodgkin
Lymphoproliferative Disorders
Neoplasms
Neoplasms by Histologic Type
Pathologic Processes
Interventions listed in this trial
ONTAK
Additional drug interventions recognized in this trial
Denileukin diftitox
More general drug interventions related to this trial
Antineoplastic Agents
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
Eisai Inc.


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services